Kenya has acquired 450,000 doses of self-injectable contraceptives, Subcutaneous Depot Medroxyprogesterone Acetate (DMPA-SC), under a UK-funded program organized by the United Nations Population Fund.
The objective of the program is to improve the availability of family planning modalities, minimize maternal deaths, and reduce the number of unplanned pregnancies. Moreover, the contraceptives were announced to safeguard 112,500 years, implying that they would have a long-term effect on family planning questions in Kenya.
According to the report, the contraceptives are meant to benefit more than 40,000 women of reproductive age, contributing to the prevention of more than 42,750 unintended pregnancies and 122 maternal deaths.
This effort is consistent with the larger goal of providing universal access to modern family planning solutions throughout Kenya. High levels of unmet need still exist, and DMPA-SC is designed to be a convenient and effective solution. Therefore, the simplicity and anonymity of self-injected contraceptives will significantly improve acceptance and compliance rates and their usage in family planning.
In addition, the initiative will fall within the scope of the commitment to the sustainable development goals by Kenya, specifically goal 3, relating to ensuring healthy lives and well-being at all ages. Prevention of unintended pregnancies and their associated health risks will contribute to improvement in maternal health indicators and, in general, support the overall development and well-being of Kenyan communities.